FUJIFILM Biosciences and NextCell Pharma AB have unveiled a global commercial rollout that tightens the link between advanced cell manufacturing tools and next-generation regenerative medicine research.

 

The launch pairs FUJIFILM Biosciences’ PRIME-XV MSC Expansion XSFM medium with NextCell’s first commercial offering, NextCell-Cord RUO—an umbilical cord–derived mesenchymal stromal cell (MSC) product designed strictly for research use.

 

The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows. 

 

By combining standardized cell sourcing with optimized expansion media, the companies aim to give researchers a more consistent and scalable foundation for work in immunology, regenerative medicine, and cell therapy development.

 

Available across major global markets through FUJIFILM Biosciences, NextCell-Cord RUO can be purchased as a standalone product or bundled with FUJIFILM Biosciences’ media, recombinant growth factors, and supporting reagents—positioning it as a plug-and-play research system for advanced cell therapy workflows.

 

“FUJIFILM Biosciences is committed to paving a better way forward with life science products, services, and solutions that serve the evolving needs of our academia, biotech, and pharmaceutical partners worldwide,” said Brandon Pence, president and chief operations officer at FUJIFILM Biosciences. 

 

“Our strategic alliance with NextCell Pharma further strengthens our commitment to enabling our customers to achieve more with products and solutions they need every day to help create a healthier world for all.”

 

“This product launch is a milestone for NextCell Pharma AB,” said Mathias Svahn, chief executive officer of NextCell Pharma AB. “It brings our proprietary MSC platform to a global audience, and we are proud to do so in close collaboration with FUJIFILM Biosciences, a trusted leader in life science solutions.”

 

“We’ve worked with FUJIFILM Biosciences to ensure that this product meets the needs of researchers and drug developers who value consistency, scalability, and translational relevance,” said Lindsay Davies, chief scientific officer at NextCell Pharma AB. 

 

“NextCell-Cord RUO reflects not only our clinical manufacturing expertise, but also a commitment to delivering high-quality, standardized MSC products that are scientifically robust and immediately usable in research and development workflows.”

 

The collaboration underscores a broader industry push toward standardization in cell therapy research—where reproducibility and scale are increasingly becoming as important as innovation itself.